APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tourette Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tourette Syndrome Drug Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchTourette Syndrome Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Tourette Syndrome Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Tourette Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tourette Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Tourette Syndrome Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Tourette Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tourette Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tourette Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tourette Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tourette Syndrome Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tourette Syndrome Drug market include Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, Synchroneuron Inc, Reviva Pharmaceuticals Inc, Psyadon Pharmaceuticals Inc, Neurocrine Biosciences Inc, Catalyst Pharmaceuticals Inc and Abide Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tourette Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tourette Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tourette Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tourette Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tourette Syndrome Drug Segment by Company

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Synchroneuron Inc

Reviva Pharmaceuticals Inc

Psyadon Pharmaceuticals Inc

Neurocrine Biosciences Inc

Catalyst Pharmaceuticals Inc

Abide Therapeutics Inc

Tourette Syndrome Drug Segment by Type

Ecopipam Hydrochloride

Dutetrabenazine ER

CPP-115

AZD-5213

Others

Tourette Syndrome Drug Segment by Application

Clinic

Hospital

Research Center

Others

Tourette Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tourette Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tourette Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tourette Syndrome Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Tourette Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tourette Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tourette Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tourette Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tourette Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tourette Syndrome Drug industry.

Chapter 3: Detailed analysis of Tourette Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tourette Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tourette Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tourette Syndrome Drug Industry Trends Table 2. Tourette Syndrome Drug Industry Drivers Table 3. Tourette Syndrome Drug Industry Opportunities and Challenges Table 4. Tourette Syndrome Drug Industry Restraints Table 5. Global Tourette Syndrome Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tourette Syndrome Drug Revenue Share by Company (2021-2026) Table 7. Global Tourette Syndrome Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Tourette Syndrome Drug Sales Volume Share by Company (2021-2026) Table 9. Global Tourette Syndrome Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Tourette Syndrome Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tourette Syndrome Drug Key Company Manufacturing Base & Headquarters Table 12. Global Tourette Syndrome Drug Company, Product Type & Application Table 13. Global Tourette Syndrome Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tourette Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ecopipam Hydrochloride Table 18. Significant Companies of Dutetrabenazine ER Table 19. Significant Companies of CPP-115 Table 20. Significant Companies of AZD-5213 Table 21. Significant Companies of Others Table 22. Global Tourette Syndrome Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Tourette Syndrome Drug Sales Volume by Type (2021-2026) & (k units) Table 24. Global Tourette Syndrome Drug Sales Volume by Type (2027-2032) & (k units) Table 25. Global Tourette Syndrome Drug Sales Volume Share by Type (2021-2026) Table 26. Global Tourette Syndrome Drug Sales Volume Share by Type (2027-2032) Table 27. Global Tourette Syndrome Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Tourette Syndrome Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Tourette Syndrome Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Tourette Syndrome Drug Sales Value Share by Type (2021-2026) Table 31. Global Tourette Syndrome Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Research Center Table 35. Significant Companies of Others Table 36. Global Tourette Syndrome Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Tourette Syndrome Drug Sales Volume by Application (2021-2026) & (k units) Table 38. Global Tourette Syndrome Drug Sales Volume by Application (2027-2032) & (k units) Table 39. Global Tourette Syndrome Drug Sales Volume Share by Application (2021-2026) Table 40. Global Tourette Syndrome Drug Sales Volume Share by Application (2027-2032) Table 41. Global Tourette Syndrome Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Tourette Syndrome Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Tourette Syndrome Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Tourette Syndrome Drug Sales Value Share by Application (2021-2026) Table 45. Global Tourette Syndrome Drug Sales Value Share by Application (2027-2032) Table 46. Global Tourette Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Tourette Syndrome Drug Sales by Region (2021-2026) & (k units) Table 48. Global Tourette Syndrome Drug Sales Market Share by Region (2021-2026) Table 49. Global Tourette Syndrome Drug Sales by Region (2027-2032) & (k units) Table 50. Global Tourette Syndrome Drug Sales Market Share by Region (2027-2032) Table 51. Global Tourette Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Tourette Syndrome Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Tourette Syndrome Drug Sales Value Share by Region (2021-2026) Table 54. Global Tourette Syndrome Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Tourette Syndrome Drug Sales Value Share by Region (2027-2032) Table 56. Global Tourette Syndrome Drug Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Tourette Syndrome Drug Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Tourette Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Tourette Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 61. Global Tourette Syndrome Drug Sales Market Share by Country (2021-2026) Table 62. Global Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 63. Global Tourette Syndrome Drug Sales Market Share by Country (2027-2032) Table 64. Global Tourette Syndrome Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Tourette Syndrome Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Tourette Syndrome Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Tourette Syndrome Drug Sales Value Market Share by Country (2027-2032) Table 68. Teva Pharmaceutical Industries Ltd Company Information Table 69. Teva Pharmaceutical Industries Ltd Business Overview Table 70. Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Product Portfolio Table 72. Teva Pharmaceutical Industries Ltd Recent Development Table 73. Therapix Biosciences Ltd Company Information Table 74. Therapix Biosciences Ltd Business Overview Table 75. Therapix Biosciences Ltd Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Therapix Biosciences Ltd Tourette Syndrome Drug Product Portfolio Table 77. Therapix Biosciences Ltd Recent Development Table 78. Synchroneuron Inc Company Information Table 79. Synchroneuron Inc Business Overview Table 80. Synchroneuron Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Synchroneuron Inc Tourette Syndrome Drug Product Portfolio Table 82. Synchroneuron Inc Recent Development Table 83. Reviva Pharmaceuticals Inc Company Information Table 84. Reviva Pharmaceuticals Inc Business Overview Table 85. Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Reviva Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 87. Reviva Pharmaceuticals Inc Recent Development Table 88. Psyadon Pharmaceuticals Inc Company Information Table 89. Psyadon Pharmaceuticals Inc Business Overview Table 90. Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 92. Psyadon Pharmaceuticals Inc Recent Development Table 93. Neurocrine Biosciences Inc Company Information Table 94. Neurocrine Biosciences Inc Business Overview Table 95. Neurocrine Biosciences Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Neurocrine Biosciences Inc Tourette Syndrome Drug Product Portfolio Table 97. Neurocrine Biosciences Inc Recent Development Table 98. Catalyst Pharmaceuticals Inc Company Information Table 99. Catalyst Pharmaceuticals Inc Business Overview Table 100. Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 102. Catalyst Pharmaceuticals Inc Recent Development Table 103. Abide Therapeutics Inc Company Information Table 104. Abide Therapeutics Inc Business Overview Table 105. Abide Therapeutics Inc Tourette Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Abide Therapeutics Inc Tourette Syndrome Drug Product Portfolio Table 107. Abide Therapeutics Inc Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Tourette Syndrome Drug Distributors List Table 111. Tourette Syndrome Drug Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Tourette Syndrome Drug Product Image Figure 2. Global Tourette Syndrome Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tourette Syndrome Drug Sales (2021-2032) & (k units) Figure 5. Global Tourette Syndrome Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Tourette Syndrome Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ecopipam Hydrochloride Image Figure 10. Dutetrabenazine ER Image Figure 11. CPP-115 Image Figure 12. AZD-5213 Image Figure 13. Others Image Figure 14. Global Tourette Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Tourette Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Tourette Syndrome Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Tourette Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tourette Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Tourette Syndrome Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Research Center Image Figure 23. Others Image Figure 24. Global Tourette Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Tourette Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Tourette Syndrome Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Tourette Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Tourette Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Tourette Syndrome Drug Sales Value Share by Application (2021-2032) Figure 30. Global Tourette Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Tourette Syndrome Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Tourette Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Tourette Syndrome Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Tourette Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Tourette Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Tourette Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Tourette Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Tourette Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Tourette Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Tourette Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Tourette Syndrome Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Tourette Syndrome Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Ecopipam Hydrochloride
  • Dutetrabenazine ER
  • CPP-115
  • AZD-5213
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Therapix Biosciences Ltd
  • Synchroneuron Inc
  • Reviva Pharmaceuticals Inc
  • Psyadon Pharmaceuticals Inc
  • Neurocrine Biosciences Inc
  • Catalyst Pharmaceuticals Inc
  • Abide Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tourette Syndrome Drug Sales Value (2021-2032)
  4. 1.2.2 Global Tourette Syndrome Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Tourette Syndrome Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tourette Syndrome Drug Market Dynamics
  1. 2.1 Tourette Syndrome Drug Industry Trends
  2. 2.2 Tourette Syndrome Drug Industry Drivers
  3. 2.3 Tourette Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Tourette Syndrome Drug Industry Restraints
3 Tourette Syndrome Drug Market by Company
  1. 3.1 Global Tourette Syndrome Drug Company Revenue Ranking in 2025
  2. 3.2 Global Tourette Syndrome Drug Revenue by Company (2021-2026)
  3. 3.3 Global Tourette Syndrome Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Tourette Syndrome Drug Average Price by Company (2021-2026)
  5. 3.5 Global Tourette Syndrome Drug Company Ranking (2024-2026)
  6. 3.6 Global Tourette Syndrome Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Tourette Syndrome Drug Company Product Type and Application
  8. 3.8 Global Tourette Syndrome Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tourette Syndrome Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tourette Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tourette Syndrome Drug Market by Type
  1. 4.1 Tourette Syndrome Drug Type Introduction
  2. 4.1.1 Ecopipam Hydrochloride
  3. 4.1.2 Dutetrabenazine ER
  4. 4.1.3 CPP-115
  5. 4.1.4 AZD-5213
  6. 4.1.5 Others
  7. 4.2 Global Tourette Syndrome Drug Sales Volume by Type
  8. 4.2.1 Global Tourette Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Tourette Syndrome Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Tourette Syndrome Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Tourette Syndrome Drug Sales Value by Type
  12. 4.3.1 Global Tourette Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Tourette Syndrome Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Tourette Syndrome Drug Sales Value Share by Type (2021-2032)
5 Tourette Syndrome Drug Market by Application
  1. 5.1 Tourette Syndrome Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.1.4 Others
  6. 5.2 Global Tourette Syndrome Drug Sales Volume by Application
  7. 5.2.1 Global Tourette Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Tourette Syndrome Drug Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Tourette Syndrome Drug Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Tourette Syndrome Drug Sales Value by Application
  11. 5.3.1 Global Tourette Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Tourette Syndrome Drug Sales Value by Application (2021-2032)
  13. 5.3.3 Global Tourette Syndrome Drug Sales Value Share by Application (2021-2032)
6 Tourette Syndrome Drug Regional Sales and Value Analysis
  1. 6.1 Global Tourette Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tourette Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tourette Syndrome Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Tourette Syndrome Drug Sales by Region (2027-2032)
  5. 6.3 Global Tourette Syndrome Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tourette Syndrome Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tourette Syndrome Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tourette Syndrome Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Tourette Syndrome Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tourette Syndrome Drug Sales Value (2021-2032)
  12. 6.6.2 North America Tourette Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tourette Syndrome Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Tourette Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tourette Syndrome Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tourette Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tourette Syndrome Drug Sales Value (2021-2032)
  21. 6.9.2 South America Tourette Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tourette Syndrome Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tourette Syndrome Drug Sales Value Share by Country, 2025 VS 2032
7 Tourette Syndrome Drug Country-level Sales and Value Analysis
  1. 7.1 Global Tourette Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tourette Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tourette Syndrome Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Tourette Syndrome Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Tourette Syndrome Drug Sales by Country (2027-2032)
  6. 7.4 Global Tourette Syndrome Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tourette Syndrome Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tourette Syndrome Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tourette Syndrome Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tourette Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tourette Syndrome Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Therapix Biosciences Ltd
  8. 8.2.1 Therapix Biosciences Ltd Company Information
  9. 8.2.2 Therapix Biosciences Ltd Business Overview
  10. 8.2.3 Therapix Biosciences Ltd Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Therapix Biosciences Ltd Tourette Syndrome Drug Product Portfolio
  12. 8.2.5 Therapix Biosciences Ltd Recent Developments
  13. 8.3 Synchroneuron Inc
  14. 8.3.1 Synchroneuron Inc Company Information
  15. 8.3.2 Synchroneuron Inc Business Overview
  16. 8.3.3 Synchroneuron Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Synchroneuron Inc Tourette Syndrome Drug Product Portfolio
  18. 8.3.5 Synchroneuron Inc Recent Developments
  19. 8.4 Reviva Pharmaceuticals Inc
  20. 8.4.1 Reviva Pharmaceuticals Inc Company Information
  21. 8.4.2 Reviva Pharmaceuticals Inc Business Overview
  22. 8.4.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  24. 8.4.5 Reviva Pharmaceuticals Inc Recent Developments
  25. 8.5 Psyadon Pharmaceuticals Inc
  26. 8.5.1 Psyadon Pharmaceuticals Inc Company Information
  27. 8.5.2 Psyadon Pharmaceuticals Inc Business Overview
  28. 8.5.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  30. 8.5.5 Psyadon Pharmaceuticals Inc Recent Developments
  31. 8.6 Neurocrine Biosciences Inc
  32. 8.6.1 Neurocrine Biosciences Inc Company Information
  33. 8.6.2 Neurocrine Biosciences Inc Business Overview
  34. 8.6.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Product Portfolio
  36. 8.6.5 Neurocrine Biosciences Inc Recent Developments
  37. 8.7 Catalyst Pharmaceuticals Inc
  38. 8.7.1 Catalyst Pharmaceuticals Inc Company Information
  39. 8.7.2 Catalyst Pharmaceuticals Inc Business Overview
  40. 8.7.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  42. 8.7.5 Catalyst Pharmaceuticals Inc Recent Developments
  43. 8.8 Abide Therapeutics Inc
  44. 8.8.1 Abide Therapeutics Inc Company Information
  45. 8.8.2 Abide Therapeutics Inc Business Overview
  46. 8.8.3 Abide Therapeutics Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Abide Therapeutics Inc Tourette Syndrome Drug Product Portfolio
  48. 8.8.5 Abide Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tourette Syndrome Drug Value Chain Analysis
  2. 9.1.1 Tourette Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tourette Syndrome Drug Sales Mode & Process
  6. 9.2 Tourette Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tourette Syndrome Drug Distributors
  9. 9.2.3 Tourette Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst